The offering attracted strong interest from the general public in Sweden and was multiple times oversubscribed, states the company.

Related article

Alvotech publish prospectus in connection with its listing on Nasdaq Stockholm

Alvotech has announced that it intends to list Swedish Depository Receipts (SDRs), equity share equivalents, on Nasdaq Stockholm.

Trading on Nasdaq Stockholm commenced May 19, 2025.

“Alvotech’s goal is to become the global leader in biosimilars development and manufacturing, providing better access to high-quality biologics for patients globally in 90 different countries, through our commercial partnerships. Today marks the next exciting step in Alvotech’s journey as the company is listed on Nasdaq Stockholm. Alvotech’s shares are now traded on three markets; Nasdaq Stockholm in Sweden, Nasdaq Global Market in the US and Nasdaq Iceland Main Market in Iceland. We think of the listing on Nasdaq Stockholm as a service to our current and future shareholders, providing better access for investors in Nordic and European markets, increasing share liquidity and broadening the shareholder base. I am delighted by the strong interest shown by investors in Sweden, and welcome the many new shareholders that subscribed to the recent offering,” says Róbert Wessman, Founder, Chairman and CEO of Alvotech.

Related article

Xbrane in agreement to sell biosimilar candidate and parts of its organization to Alvotech

Xbrane Biopharma has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees and laboratory equipment, to Alvotech for a total consideration of approximately SEK 275 million.